Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930472 | 0.94 | KDM4E (0.46) | NOS1KDM4EHTTKMT2ACHRNB2 | |
| SCHEMBL14930518 | 0.94 | KDM4E (0.46) | NOS1KDM4EHTTKMT2ACHRNB2 | |
| SCHEMBL14930443 | 0.91 | ACACB (0.46) | NOS1KDM4EHTTKMT2ACHRNB2 | |
| SCHEMBL14232317 | 0.84 | KDM4E (0.47) | KDM4EHTTKMT2ACHRNB2CHRNB4 | |
| SCHEMBL8339774 | 0.82 | MAPT (0.52) | KDM4ELTA4H | |
| SCHEMBL1535647 | 0.82 | KDM4E (0.54) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL12409185 | 0.82 | CHRNB2 (0.54) | NOS1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12016106 | 0.82 | CYP1A1 (0.60) | NOS1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15723550 | 0.82 | SMN1; SMN2 (0.56) | KDM4EHTTKMT2AALDH1A1 | |
| SCHEMBL4867973 | 0.82 | MAOB (0.49) | NOS1KMT2ACHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022224212-A1 | GPR35 AGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-27 | — | — | WO | disclosed |
| CN-105073715-A | Dihydropyridazine-3,5-dione derivative | CHUGAI PHARMACEUTICAL CO LTD | 2015-11-18 | — | — | CN | disclosed |
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| WO-2009149508-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | NOS1 2311/4885KDM4E 653/4885HTT 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.